AAPL327.44-6.30 (-1.89%) ▼|ABBV254.00-0.49 (-0.19%) ▼|ABT101.20+0.52 (+0.51%) ▲|ACN141.65-1.92 (-1.34%) ▼|ADBE228.72-8.53 (-3.60%) ▼|AMAT538.27+8.61 (+1.63%) ▲|AMD511.80+16.04 (+3.23%) ▲|AMGN366.92+0.63 (+0.17%) ▲|AMT168.89-1.17 (-0.69%) ▼|AMZN249.62+2.39 (+0.97%) ▲|AVGO378.57+7.75 (+2.09%) ▲|AXP353.16-2.20 (-0.62%) ▼|BA209.73-4.30 (-2.01%) ▼|BAC60.71-0.56 (-0.91%) ▼|BKNG179.14-2.54 (-1.40%) ▼|BLK1,057.21-14.99 (-1.40%) ▼|BMY61.25+0.51 (+0.84%) ▲|BNY157.78+0.65 (+0.41%) ▲|BRK-B490.83-0.08 (-0.02%) ▼|C129.51+0.15 (+0.12%) ▲|CAT879.13+0.48 (+0.05%) ▲|CL91.73-0.72 (-0.78%) ▼|CMCSA23.64-0.16 (-0.65%) ▼|COF207.61-0.42 (-0.20%) ▼|COP115.18+0.47 (+0.41%) ▲|COST944.73+3.86 (+0.41%) ▲|CRM168.87-1.90 (-1.11%) ▼|CSCO112.52+0.58 (+0.52%) ▲|CVS108.01+0.54 (+0.50%) ▲|CVX188.51+1.13 (+0.60%) ▲|DE591.17-6.07 (-1.02%) ▼|DHR203.49-0.34 (-0.17%) ▼|DIS96.40-1.27 (-1.30%) ▼|DUK126.68+1.67 (+1.34%) ▲|EMR137.09-2.45 (-1.76%) ▼|FDX308.61-4.38 (-1.40%) ▼|GD371.98+3.40 (+0.92%) ▲|GE347.96-0.87 (-0.25%) ▼|GEV1,081.24+23.40 (+2.21%) ▲|GILD133.87-0.41 (-0.31%) ▼|GM76.01-0.06 (-0.08%) ▼|GOOG358.50+12.38 (+3.58%) ▲|GOOGL358.73+11.96 (+3.45%) ▲|GS1,060.00-5.22 (-0.49%) ▼|HD335.22-3.65 (-1.08%) ▼|HON225.17+0.15 (+0.07%) ▲|IBM210.51-2.17 (-1.02%) ▼|INTC97.78+2.74 (+2.88%) ▲|INTU282.98-8.12 (-2.79%) ▼|ISRG346.67+1.25 (+0.36%) ▲|JNJ251.70-1.34 (-0.53%) ▼|JPM341.29+0.19 (+0.06%) ▲|KO82.17+0.61 (+0.75%) ▲|LIN515.25+2.03 (+0.40%) ▲|LLY1,169.32-9.79 (-0.83%) ▼|LMT511.67+2.90 (+0.57%) ▲|LOW204.39-4.35 (-2.08%) ▼|LRCX312.98-0.33 (-0.10%) ▼|MA542.86-0.75 (-0.14%) ▼|MCD268.87+1.16 (+0.43%) ▲|MDLZ60.29-0.71 (-1.16%) ▼|MDT83.32+0.12 (+0.14%) ▲|META643.84-2.17 (-0.34%) ▼|MMM161.29+1.45 (+0.91%) ▲|MO74.58+0.37 (+0.50%) ▲|MRK126.61-0.89 (-0.70%) ▼|MS213.84-1.67 (-0.77%) ▼|MSFT394.25+0.43 (+0.11%) ▲|MU872.51+23.56 (+2.77%) ▲|NEE89.30+0.50 (+0.56%) ▲|NFLX67.54-1.41 (-2.05%) ▼|NKE43.12-0.64 (-1.46%) ▼|NOW99.07-4.17 (-4.04%) ▼|NVDA205.22+2.41 (+1.19%) ▲|ORCL120.58-5.83 (-4.61%) ▼|PEP136.64-0.49 (-0.35%) ▼|PFE24.94-0.12 (-0.46%) ▼|PG149.62-0.36 (-0.24%) ▼|PLTR132.80+0.42 (+0.32%) ▲|PM193.05+0.07 (+0.04%) ▲|QCOM171.76-0.02 (-0.01%) ▼|RTX196.71+3.20 (+1.65%) ▲|SBUX106.09+0.60 (+0.57%) ▲|SCHW100.49-1.07 (-1.05%) ▼|SO95.43+0.13 (+0.14%) ▲|SPG230.04+1.34 (+0.59%) ▲|T21.83+0.02 (+0.09%) ▲|TMO529.02-3.47 (-0.65%) ▼|TMUS193.04+0.61 (+0.32%) ▲|TSLA374.72-6.13 (-1.61%) ▼|TXN289.55+5.53 (+1.95%) ▲|UBER72.23-0.23 (-0.32%) ▼|UNH422.09-4.00 (-0.94%) ▼|UNP300.40-1.35 (-0.45%) ▼|UPS113.72-4.00 (-3.40%) ▼|USB63.27+0.13 (+0.21%) ▲|V359.07+0.51 (+0.14%) ▲|VZ43.48-0.12 (-0.26%) ▼|WFC86.96-0.55 (-0.63%) ▼|WMT113.99-0.25 (-0.22%) ▼|XOM148.37+1.01 (+0.68%) ▲|AAPL327.44-6.30 (-1.89%) ▼|ABBV254.00-0.49 (-0.19%) ▼|ABT101.20+0.52 (+0.51%) ▲|ACN141.65-1.92 (-1.34%) ▼|ADBE228.72-8.53 (-3.60%) ▼|AMAT538.27+8.61 (+1.63%) ▲|AMD511.80+16.04 (+3.23%) ▲|AMGN366.92+0.63 (+0.17%) ▲|AMT168.89-1.17 (-0.69%) ▼|AMZN249.62+2.39 (+0.97%) ▲|AVGO378.57+7.75 (+2.09%) ▲|AXP353.16-2.20 (-0.62%) ▼|BA209.73-4.30 (-2.01%) ▼|BAC60.71-0.56 (-0.91%) ▼|BKNG179.14-2.54 (-1.40%) ▼|BLK1,057.21-14.99 (-1.40%) ▼|BMY61.25+0.51 (+0.84%) ▲|BNY157.78+0.65 (+0.41%) ▲|BRK-B490.83-0.08 (-0.02%) ▼|C129.51+0.15 (+0.12%) ▲|CAT879.13+0.48 (+0.05%) ▲|CL91.73-0.72 (-0.78%) ▼|CMCSA23.64-0.16 (-0.65%) ▼|COF207.61-0.42 (-0.20%) ▼|COP115.18+0.47 (+0.41%) ▲|COST944.73+3.86 (+0.41%) ▲|CRM168.87-1.90 (-1.11%) ▼|CSCO112.52+0.58 (+0.52%) ▲|CVS108.01+0.54 (+0.50%) ▲|CVX188.51+1.13 (+0.60%) ▲|DE591.17-6.07 (-1.02%) ▼|DHR203.49-0.34 (-0.17%) ▼|DIS96.40-1.27 (-1.30%) ▼|DUK126.68+1.67 (+1.34%) ▲|EMR137.09-2.45 (-1.76%) ▼|FDX308.61-4.38 (-1.40%) ▼|GD371.98+3.40 (+0.92%) ▲|GE347.96-0.87 (-0.25%) ▼|GEV1,081.24+23.40 (+2.21%) ▲|GILD133.87-0.41 (-0.31%) ▼|GM76.01-0.06 (-0.08%) ▼|GOOG358.50+12.38 (+3.58%) ▲|GOOGL358.73+11.96 (+3.45%) ▲|GS1,060.00-5.22 (-0.49%) ▼|HD335.22-3.65 (-1.08%) ▼|HON225.17+0.15 (+0.07%) ▲|IBM210.51-2.17 (-1.02%) ▼|INTC97.78+2.74 (+2.88%) ▲|INTU282.98-8.12 (-2.79%) ▼|ISRG346.67+1.25 (+0.36%) ▲|JNJ251.70-1.34 (-0.53%) ▼|JPM341.29+0.19 (+0.06%) ▲|KO82.17+0.61 (+0.75%) ▲|LIN515.25+2.03 (+0.40%) ▲|LLY1,169.32-9.79 (-0.83%) ▼|LMT511.67+2.90 (+0.57%) ▲|LOW204.39-4.35 (-2.08%) ▼|LRCX312.98-0.33 (-0.10%) ▼|MA542.86-0.75 (-0.14%) ▼|MCD268.87+1.16 (+0.43%) ▲|MDLZ60.29-0.71 (-1.16%) ▼|MDT83.32+0.12 (+0.14%) ▲|META643.84-2.17 (-0.34%) ▼|MMM161.29+1.45 (+0.91%) ▲|MO74.58+0.37 (+0.50%) ▲|MRK126.61-0.89 (-0.70%) ▼|MS213.84-1.67 (-0.77%) ▼|MSFT394.25+0.43 (+0.11%) ▲|MU872.51+23.56 (+2.77%) ▲|NEE89.30+0.50 (+0.56%) ▲|NFLX67.54-1.41 (-2.05%) ▼|NKE43.12-0.64 (-1.46%) ▼|NOW99.07-4.17 (-4.04%) ▼|NVDA205.22+2.41 (+1.19%) ▲|ORCL120.58-5.83 (-4.61%) ▼|PEP136.64-0.49 (-0.35%) ▼|PFE24.94-0.12 (-0.46%) ▼|PG149.62-0.36 (-0.24%) ▼|PLTR132.80+0.42 (+0.32%) ▲|PM193.05+0.07 (+0.04%) ▲|QCOM171.76-0.02 (-0.01%) ▼|RTX196.71+3.20 (+1.65%) ▲|SBUX106.09+0.60 (+0.57%) ▲|SCHW100.49-1.07 (-1.05%) ▼|SO95.43+0.13 (+0.14%) ▲|SPG230.04+1.34 (+0.59%) ▲|T21.83+0.02 (+0.09%) ▲|TMO529.02-3.47 (-0.65%) ▼|TMUS193.04+0.61 (+0.32%) ▲|TSLA374.72-6.13 (-1.61%) ▼|TXN289.55+5.53 (+1.95%) ▲|UBER72.23-0.23 (-0.32%) ▼|UNH422.09-4.00 (-0.94%) ▼|UNP300.40-1.35 (-0.45%) ▼|UPS113.72-4.00 (-3.40%) ▼|USB63.27+0.13 (+0.21%) ▲|V359.07+0.51 (+0.14%) ▲|VZ43.48-0.12 (-0.26%) ▼|WFC86.96-0.55 (-0.63%) ▼|WMT113.99-0.25 (-0.22%) ▼|XOM148.37+1.01 (+0.68%) ▲|
24.9 C
New York
Monday, July 20, 2026

Tag: carcinoma

newssourceFORcompanyinformationcontent1releasesmarket

TWL Announces Expanded Online Access to GLP-1 Weight-Loss Care With Insurance and Self-Pay Options

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients 
Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients

AM Rx Announces Expanded Online Access and Insurance Support for Zepbound

Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care 
Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Canada’s Largest Athletic Fundraiser Raises a Record $23.3 Million in Support of The Princess Margaret Cancer Foundation

More than 4800 cyclists set a new fundraising record to create a world free from the fear of cancer TORONTO, June 13, 2026 /CNW/...

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCarcinoma

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers